These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 11723619)
21. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Schneider DJ; Aggarwal A Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):903-13. PubMed ID: 15500435 [TBL] [Abstract][Full Text] [Related]
22. Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban. Hölschermann H; Krombach C; Jung A; Jacobi F; Tillmanns H; Weinand F Thromb Haemost; 2005 Sep; 94(3):684-6. PubMed ID: 16268493 [No Abstract] [Full Text] [Related]
23. [Update on tirofiban]. Danchin N Presse Med; 2001 Jan; 30(2):93-4. PubMed ID: 11244822 [No Abstract] [Full Text] [Related]
24. Should patients with unstable coronary syndromes routinely undergo cardiac catheterization and appropriate revascularization? Gazewood J J Fam Pract; 2001 Sep; 50(9):739. PubMed ID: 11674901 [No Abstract] [Full Text] [Related]
25. Two i.v. antiplatelet agents marketed for coronary disease. Am J Health Syst Pharm; 1998 Jul; 55(14):1440, 1443. PubMed ID: 9676283 [No Abstract] [Full Text] [Related]
26. IIb/IIIa or not IIb/IIIa? That is the question. Redwood S Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749 [No Abstract] [Full Text] [Related]
27. Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment. Yang TY; Chang ST; Chung CM; Cheng NJ Int Heart J; 2005 Jan; 46(1):139-45. PubMed ID: 15858946 [TBL] [Abstract][Full Text] [Related]